Selecta Biosciences, Inc. (NASDAQ:SELB) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET

Company Participants

Blaine Davis - Chief Financial Officer

Carsten Brunn - President, Chief Executive Officer & Director

Peter Traber - Chief Medical Officer

Conference Call Participants

Joseph Schwartz - SVB Securities

Kristen Kluska - Cantor Fitzgerald

John Newman - Canaccord Genuity

Yun Zhong - BTIG

Gil Blum - Needham & Company

Tiffany Marchell - William Blair

Boobalan Pachaiyappan - H.C. Wainwright

Uy Ear - Mizuho

Operator

Good morning, and welcome to the Selecta Bio Fourth Quarter 2022 Earnings Release Conference Call. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Blaine Davis, Chief Financial Officer. Please go ahead.

Blaine Davis

Thank you, and good morning, everyone. Welcome to our fourth quarter and full year 2022 Financial Results and Business Update Conference Call. The press release reporting our financial results is available in the Investors and Media section of Selecta's website at www.selectabio.com in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed earlier this morning with the Securities and Exchange Commission or the SEC. Joining me on today's call are Carsten Brunn, President and Chief Executive Officer; Kei Kishimoto, Chief Scientific Officer; and Peter Traber, our Chief Medical Officer.

During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety, efficacy and regulatory and clinical progress of our product candidates, our financial projections and our future expectations, plans, partnerships and prospects. These statements are subject to various risks that are described in the filings made with the SEC, including our most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, March 2, 2023, and Selecta disclaims any obligation to update such statements, except as required by law, even if management's views change.

With that, I'd now like to turn the call over to Carsten.

Carsten Brunn

Thank you, Blaine. Good morning. I appreciate everyone taking the time to join us today. In the fourth quarter of 2022 and in the first months of 2023, we continue to make steady progress across our pipeline, and we believe we’re well-positioned to execute on our key priorities and reach multi milestones throughout this year. In collaboration with our partner, Sobi, we expect to announce top line data from the Phase III DISSOLVE I and II clinical trials of SEL-212 later this quarter. We remain blinded [ph] to the data based on the results from previous trials in which we observed SEL-212’s differentiated profile and convenient once-monthly dosing regimen, we remain confident in its potential to improve the lives of patients suffering from chronic refractory gout.